Bioinformatics analysis of dysregulated microRNAs in exosomes from docetaxel-resistant and parental human breast cancer cells

References

• DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin 2017;67(6):439–448. doi:10.3322/caac.21412
   Google Scholar
• Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615–627. doi:10.1146/annurev.med.53.082901.10392911818492
   PubMed Web of Science ®Google Scholar
• Tkach M, Thery C. Communication by extracellular vesicles: where we are and where we need to go. Cell. 2016;164(6):1226–1232. doi:10.1016/j.cell.2016.01.04326967288
   PubMed Web of Science ®Google Scholar
• Chin AR, Wang SE. Cancer-derived extracellular vesicles: the “soil conditioner” in breast cancer metastasis? Cancer Metastasis Rev. 2016;35(4):669–676. doi:10.1007/s10555-016-9639-827838868
   PubMed Web of Science ®Google Scholar
• Chen WX, Zhong SL, Ji MH, et al. MicroRNAs delivered by extracellular vesicles: an emerging resistance mechanism for breast cancer. Tumour Biol. 2014;35(4):2883–2892. doi:10.1007/s13277-013-1417-424272085
   PubMed Web of Science ®Google Scholar
• Santos JC, Ribeiro ML, Sarian LO, Ortega MM, Derchain SF. Exosomes-mediate microRNAs transfer in breast cancer chemoresistance regulation. Am J Cancer Res. 2016;6(10):2129–2139.27822407
   PubMed Web of Science ®Google Scholar
• Zhong S, Chen X, Wang D, et al. MicroRNA expression profiles of drug-resistance breast cancer cells and their exosomes. Oncotarget. 2016;7(15):19601–19609. doi:10.18632/oncotarget.748126910922
   PubMedGoogle Scholar
• Li XJ, Ren ZJ, Tang JH, Yu Q. Exosomal MicroRNA MiR-1246 promotes cell proliferation, invasion and drug resistance by targeting CCNG2 in breast cancer. Cell Physiol Biochem. 2017;44(5):1741–1748. doi:10.1159/00048578029216623
   PubMedGoogle Scholar
• Wei Y, Lai X, Yu S, et al. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. Breast Cancer Res Treat. 2014;147(2):423–431. doi:10.1007/s10549-014-3037-025007959
   PubMed Web of Science ®Google Scholar
• Chen WX, Cai YQ, Lv MM, et al. Exosomes from docetaxel-resistant breast cancer cells alter chemosensitivity by delivering microRNAs. Tumour Biol. 2014;35(10):9649–9659. doi:10.1007/s13277-014-2242-024969560
   PubMedGoogle Scholar
• Wang X, Zhang H, Bai M, et al. Exosomes serve as nanoparticles to deliver Anti-miR-214 to reverse chemoresistance to cisplatin in gastric cancer. Mol Ther. 2018;26(3):774–783. doi:10.1016/j.ymthe.2018.01.00129456019
   PubMed Web of Science ®Google Scholar
• Li WJ, Zhong SL, Wu YJ, et al. Systematic expression analysis of genes related to multidrug-resistance in isogenic docetaxel- and adriamycin-resistant breast cancer cell lines. Mol Biol Rep. 2013;40(11):6143–6150. doi:10.1007/s11033-013-2725-x24078162
   PubMed Web of Science ®Google Scholar
• Corcoran C, Rani S, O’Brien K, et al. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS One. 2012;7(12):e50999. doi:10.1371/journal.pone.005099923251413
   PubMed Web of Science ®Google Scholar
• Zhong S, Li W, Chen Z, Xu J, Zhao J. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. Gene. 2013;531(1):8–14. doi:10.1016/j.gene.2013.08.06223994196
   PubMed Web of Science ®Google Scholar
• Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42(Database issue):D92–D97. doi:10.1093/nar/gkt124824297251
   PubMed Web of Science ®Google Scholar
• Huang DW, Sherman BT, Tan Q, et al. DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res. 2007;35(Web Server issue):W169–W175. doi:10.1093/nar/gkm41517576678
   PubMed Web of Science ®Google Scholar
• Kanehisa M, Araki M, Goto S, et al. KEGG for linking genomes to life and the environment. Nucleic Acids Res. 2008;36(Database issue):D480–D484. doi:10.1093/nar/gkm88218077471
   PubMed Web of Science ®Google Scholar
• Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25–29. doi:10.1038/7555610802651
   PubMed Web of Science ®Google Scholar
• Saito R, Smoot ME, Ono K, et al. A travel guide to Cytoscape plugins. Nat Methods. 2012;9(11):1069–1076. doi:10.1038/nmeth.221223132118
   PubMed Web of Science ®Google Scholar
• Benito-Martin A, Peinado H. FunRich proteomics software analysis, let the fun begin! Proteomics. 2015;15(15):2555–2556. doi:10.1002/pmic.v15.1526149235
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Franceschini A, Kuhn M, et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 2011;39(Database issue):D561–D568. doi:10.1093/nar/gkq97321045058
   PubMed Web of Science ®Google Scholar
• Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004;4(12):937–947. doi:10.1038/nrc150315573115
   PubMed Web of Science ®Google Scholar
• Wang SE, Xiang B, Guix M, et al. Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol. 2008;28(18):5605–5620. doi:10.1128/MCB.00787-0818625725
   PubMed Web of Science ®Google Scholar
• Coomans de Brachene A, Demoulin JB. FOXO transcription factors in cancer development and therapy. Cell Mol Life Sci. 2016;73(6):1159–1172. doi:10.1007/s00018-015-2112-y26686861
   PubMed Web of Science ®Google Scholar
• Loh YN, Hedditch EL, Baker LA, Jary E, Ward RL, Ford CE. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. BMC Cancer. 2013;13:174. doi:10.1186/1471-2407-13-17423547709
   PubMed Web of Science ®Google Scholar
• Dey N, De P, Leyland-Jones B. PI3K-AKT-mTOR inhibitors in breast cancers: from tumor cell signaling to clinical trials. Pharmacol Ther. 2017;175:91–106. doi:10.1016/j.pharmthera.2017.02.03728216025
   PubMed Web of Science ®Google Scholar
• Korkaya H, Liu S, Wicha MS. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest. 2011;121(10):3804–3809. doi:10.1172/JCI5787321965337
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.01321376230
   PubMed Web of Science ®Google Scholar
• Safe S, Abbruzzese JL, Abdelrahim M, Hedrick E. Specificity protein transcription factors and cancer: opportunities for drug development. Cancer Prev Res (Phila). 2018;11:371–382. doi:10.1158/1940-6207.CAPR-17-040729545399
   PubMed Web of Science ®Google Scholar
• Lasham A, Mehta SY, Fitzgerald SJ, et al. A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line. Int J Cancer. 2016;139(5):1157–1170. doi:10.1002/ijc.3013727072400
   PubMed Web of Science ®Google Scholar
• Elsheikh S, Green AR, Aleskandarany MA, et al. CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Res Treat. 2008;109(2):325–335. doi:10.1007/s10549-007-9659-817653856
   PubMed Web of Science ®Google Scholar
• Wang G, Gormley M, Qiao J, et al. Cyclin D1-mediated microRNA expression signature predicts breast cancer outcome. Theranostics. 2018;8(8):2251–2263. doi:10.7150/thno.2387729721077
   PubMed Web of Science ®Google Scholar
• Xu F, Zhang C, Cui J, Liu J, Li J, Jiang H. The prognostic value and potential drug target of phosphatase and tensin homolog in breast cancer patients: a meta-analysis. Medicine. 2017;96(36):e8000. doi:10.1097/MD.000000000000800028885360
   PubMed Web of Science ®Google Scholar